RDY
· Pharmaceuticals
Dr. Reddy's Laboratories
$13.28
-0.19 (-1.41%)
Financial Highlights (FY 2026)
Revenue
31.32T
Net Income
5.43T
Gross Margin
67.0%
Profit Margin
17.3%
Rev Growth
+14.9%
D/E Ratio
0.14
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | |
|---|---|---|
| Gross Margin | 67.0% | 67.0% |
| Operating Margin | 21.0% | 18.9% |
| Profit Margin | 17.3% | 16.5% |
Income Statement
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 31.32T | 27.27T |
| Gross Profit | 20.98T | 18.26T |
| Operating Income | 6.56T | 5.14T |
| Net Income | 5.43T | 4.25T |
| Gross Margin | 67.0% | 67.0% |
| Operating Margin | 21.0% | 18.9% |
| Profit Margin | 17.3% | 16.5% |
| Rev Growth | +14.9% | +14.9% |
Balance Sheet
| FY 2026 | FY 2025 | |
|---|---|---|
| Total Debt | 66.44B | 66.44B |
| Total Equity | 476.61B | 476.61B |
| D/E Ratio | 0.14 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | |
|---|---|---|
| EBITDA | 8.53T | 7.05T |
| Free Cash Flow | — | — |